Standard Chem. & Pharm. Co., Ltd.
_________________________________________________________________________________
Standard Chem. & Pharm. Co., Ltd. Financial Snapshot
Operating Performance
Fast Facts
The company reported revenue of US$91.74 million
Headquarters Address No.6-20, Sinying City, 73055,Taiwan
during the fiscal year 2010 (2010). The company's
revenue grew at a CAGR of 11.60% during 2006–
Telephone + 886 6 6361511
2010, with an annual growth of 32.80% over 2009. In
2010, the company recorded an operating margin of
Fax + 886 6 6329953 11.02%, as against 13.25% in 2009.
Website www.standard.com.tw
Revenue and Margins
Ticker Symbol, Stock Exchange 1720, Taiwan Stock Exchange
Number of Employees 830
Fiscal Year End December
Revenue (in US$ million) 91.74
Revenue (in TWD million) 2,894.48
SWOT Analysis Return on Equity
Strengths Weaknesses The company recorded a return on equity (ROE) of
7.78% for 2010, as compared to its peers, Takeda
Broad product portfolio Decline in margins Pharmaceutical Company Limited (Ticker: 4502),
Astellas Pharma Inc. (Ticker: 4503) and China
Chemical & Pharmaceutical Co. Ltd. (Ticker: 1701),
Focus on quality and food safety Declining liquidity position which recorded ROEs of 14.04%, 11.60% and 7.90%
respectively. The company reported an operating
Geographically diversified operations Weakening solvency position margin of 11.02% in 2010.
Strengthening efficiency Return on Equity
Opportunities Threats
Growing cosmetics market in Asia Rising labor costs in the US
Increase in healthcare spending Consolidation within the industry
Joint venture with DIA Pharmaceutical
Illicit pharmaceutical ingredients trading
Co Ltd
Liquidity Position
The company reported a current ratio of 2.28 in 2010,
as compared to its peers, Takeda Pharmaceutical
Company Limited, Astellas Pharma Inc. and China
Chemical & Pharmaceutical Co. Ltd., which recorded
current ratios of 3.67, 3.57 and 1.21 respectively. As
of December 2010, the company recorded cash and
short-term investments of worth US$34.44 million,
against zero current debt. The company reported a
debt to equity ratio of 0.33 in 2010 as compared to its
peers, Takeda Pharmaceutical Company Limited,
Astellas Pharma Inc. and China Chemical &
Pharmaceutical Co. Ltd., which recorded debt to
equity ratios of 0.01, 0.00 and 0.35 respectively.
_______________________________________________________________________________